Table 3.
Prebiologic Asthma-related Outcomes Used in Remission Definitions
| Total (N = 3,717) | Anti-IgE (n = 1,390) | Anti-IL5/5R (n = 2,021) | Anti-IL4Rα (n = 306) | |
|---|---|---|---|---|
| Pre-Bx exacerbations,* N | 2,351 | 777 | 1,382 | 192 |
| 0 | 610 (25.9) | 221 (28.4) | 286 (20.7) | 103 (53.6) |
| 1 (not hospitalized) | 364 (15.5) | 126 (16.2) | 191 (13.8) | 47 (24.5) |
| 2 (not hospitalized) | 307 (13.1) | 100 (12.9) | 186 (13.5) | 21 (10.9) |
| ⩾1 (hospitalized) or ⩾3 in total | 1,070 (45.5) | 330 (42.5) | 719 (52.0) | 21 (10.9) |
| Pre-Bx LTOCS* dose, N | 3,094 | 1,076 | 1,824 | 194 |
| 0 mg/d (nonuser) | 1,852 (59.9) | 729 (67.8) | 974 (53.4) | 149 (76.8) |
| ⩽5 mg/d | 332 (10.7) | 98 (9.1) | 218 (12.0) | 16 (8.2) |
| >5 to 10 mg/d | 365 (11.8) | 100 (9.3) | 252 (13.8) | 13 (6.7) |
| >10 mg/d | 362 (11.7) | 105 (9.8) | 242 (13.3) | 15 (7.7) |
| User but missing dose | 183 (5.9) | 44 (4.1) | 138 (7.6) | 1 (0.5) |
| Pre-Bx asthma control,†‡ N | 1,808 | 637 | 1,095 | 76 |
| Well controlled | 189 (10.5) | 73 (11.5) | 104 (9.5) | 12 (15.8) |
| Partly controlled | 309 (17.1) | 88 (13.8) | 202 (18.4) | 19 (25.0) |
| Uncontrolled | 1,310 (72.5) | 476 (74.7) | 789 (72.1) | 45 (59.2) |
| Pre-Bx ppFEV1,†§ N | 2,705 | 995 | 1,472 | 238 |
| ⩾80% | 1,126 (41.6) | 412 (41.4) | 599 (40.7) | 115 (48.3) |
| <80% | 1,579 (58.4) | 583 (58.6) | 873 (59.3) | 123 (51.7) |
Definition of abbreviations: ACQ = Asthma Control Questionnaire; ACT = Asthma Control Test; Bx = biologic; GINA = Global Initiative for Asthma; LTOCS = long-term oral corticosteroid; ppFEV1 = percent predicted FEV1.
Data are presented as n (%) unless otherwise noted.
In the year preceding biologic initiation.
In the year preceding and closest to biologic initiation.
Assessed using either GINA control criteria (30), ACT (48), or ACQ (49). ACQ and/or ACT control categories were fitted to GINA 2020 control categories as follows: mean ACQ: well controlled (⩽0.75), partly controlled (>0.75 to <1.5), uncontrolled (⩾1.5). Total ACT: well controlled (>19), partly controlled (>15 to ⩽19), uncontrolled (⩽15).
Post-bronchodilator used if available, and prebronchodilator used otherwise, while ensuring that pre- and postbiologic measures were both either pre- or post-bronchodilator. Post-bronchodilator measurements were used for 61.6% of patients with available prebiologic ppFEV1 (n = 2,705). The remaining 38.4% of patients were all treated with inhaled corticosteroid/long-acting β2-agonist (i.e., bronchodilator not specifically withheld).